Discover and read the best of Twitter Threads about #Prodige7
Most recents (1)
Finally, #Prodige7 results are out at @TheLancetOncol!
This is a giant step forward building evidence on Peritoneal Metastases of CRC origin.
French groups have to be congratulated for this outstanding work.
@RENAPE_Network & @GroupeUNICANCER-GI
doi.org/10.1016/S1470-…
This is a giant step forward building evidence on Peritoneal Metastases of CRC origin.
French groups have to be congratulated for this outstanding work.
@RENAPE_Network & @GroupeUNICANCER-GI
doi.org/10.1016/S1470-…
#Prodige7 is the 1st prospective study to report these excellent survival outcomes in PM of CRC origin:
-Median OS: 41'2-41-7 months
-1y OS: 86'9-88'3%
-5y OS: 36'7-39.4%
Relapse-free survival is astonishing too:
-Median RFS: 11'1-13'1 months
-1y RFS: 46'1-59%
-5y RFS: 13'1-14'8%
-Median OS: 41'2-41-7 months
-1y OS: 86'9-88'3%
-5y OS: 36'7-39.4%
Relapse-free survival is astonishing too:
-Median RFS: 11'1-13'1 months
-1y RFS: 46'1-59%
-5y RFS: 13'1-14'8%
Although there is no difference regarding OS, RFS or PFS between cytoreductive surgery alone VS Oxaliplatin-based HIPEC.
There is room for hope and new research regarding PCI 11-15 where HIPEC does better in OS and RFS than surgery alone.
There is room for hope and new research regarding PCI 11-15 where HIPEC does better in OS and RFS than surgery alone.
